Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T14:57:22.875Z.
Calculation as of: 2026-10-06T14:57:22.875Z.
Quote observation: 2026-10-06T14:49:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 581b2fbaae035830ca35d06372124b56c7048e0f0ab23ef832a371d1053372ba
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$14.01M
EBITDA Yield
N/A
TTM Avg
0.87%
3Y Avg
0.87%
5Y Avg
0.87%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IN8bio, Inc. (INAB) | $13.62M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.72M | N/A | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.25M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.01M | N/A | 0.87% | 0.87% | 0.87% |
| Cytosorbents Corporation (CTSO)vs › | $13.10M | N/A | N/A | N/A | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.86M | N/A | N/A | N/A | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.39M | N/A | N/A | N/A | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.56M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.44M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.17M | N/A | 0.96% | 2.71% | 3.80% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
